Abstract: Assays that can measure the effect of proteasome inhibitors on target cells in a biological sample are provided. The assays include evaluation of the effects of proteasome inhibitors on proteasome activity in cells in a biological sample.

Abstract: A portable, handheld device for fluorescence-based imaging is provided. The device comprises a wireless communication device having a sensor configured to detect optical signals. The device further comprises an assembly configured to receive and secure the wireless communication device therein. The assembly includes a housing, at least one light source coupled to the housing, a power supply, and an optical filter holder coupled to the housing and configured to receive one or more optical filters. An endoscope portion of the device is positioned relative to the sensor to visualize at least a portion of a confined anatomical space and to receive optical signals from a visualized, illuminated portion of a target positioned within the confined anatomical space. A processor of the device includes image analysis software and is configured to produce a composite representation of the illuminated portion of the target positioned within the confined anatomical space.

Abstract: Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.

Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

Abstract: An apparatus for high resolution positron emission tomography (PET) imaging. The apparatus includes at least a first detector and a second detector arranged to detect gamma rays traveling from a target area, the first detector and the second detector being a detector pair. There is at least one collimator for filtering gamma rays reaching the first and second detectors. The collimator defines respective passages filtering gamma rays reaching the respective first and second detectors, the passages being defined to filter for only gamma ray pairs traveling from the target area at a predetermined range of angles with respect to each other, the predetermined range of angles being in the range of 180°-?E, where ?E is less than 1° and greater than 0°.

Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b.

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR-primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.

Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

Abstract: Disclosed is a mask for use in respiratory monitoring and/or diagnostics. The mask comprises at least one transducer responsive to sound and/or airflow for generating a signal, and a support structure to rest on the subject's face. In one embodiment, the support structure comprises two or more limbs that provide a transducer support for supporting the transducer at a distance from a nose and mouth area, allowing monitoring via the transducer of sound and/or airflow produced by the subject. Also described is a mask comprising a transducer responsive to airflow for generating a signal and a support structure to rest on the subject's face and extend outwardly over a nose and mouth area to provide a transducer support supporting the transducer at a distance from a nose and mouth area of the subject's face and at a preset orientation, for monitoring via the transducer of airflow produced by the subject.

Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract: A coil electrode for use with an RFA (radio frequency ablation) apparatus, has a lead portion, and a helical portion coupled to the lead portion, the helical portion being formed of Nitinol SE510. Further, an RFA (radio frequency ablation) apparatus, comprises an applicator, the applicator including a handle and a cannulating delivery needle mounted to the handle, the cannulating delivery needle including a tip spaced apart from the handle. A coil electrode includes a lead portion housed in the cannulating delivery needle, and a helical portion coupled to the lead portion, the helical portion formed of Nitinol. The helical portion has a retracted state when housed within the cannulating delivery needle and a deployed state when moved out of the tip of the cannulating delivery needle.

Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.

Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.

Abstract: The present application relates to imidazolidinecliones, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullination of proteins by peptidyl arginine deiminase (PAD) enzymes. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: (I).

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: Various embodiments are described herein for an apparatus and a method for measuring and characterizing geometric distortions for a region of interest in images obtained using magnetic resonance. The method comprises deriving a computed set of 3D distortion vectors for a set of points within a region of interest covered by a phantom by using harmonic analysis to solve an associated boundary value problem based on boundary conditions derived from a measured set of 3D distortion vectors. The characterized image distortions may be used for various purposes such as for image correction or for shimming, for example.